Introduction
Low-dose weekly methotrexate (MTX) is widely used researchers to speculate that folic acid analogues could be useful in treating this form of malignancy. in the treatment of rheumatoid arthritis1 and is now Paradoxically, it was found that a folate-deficient increasingly used in other rheumatic conditions, diet could cause depletion of leukaemic cell lines, including systemic lupus erythematosus and juvenile which led to the use of the competitive analogues arthritis. Because of its anti-metabolic and cytotoxic in haematological malignancies.4 actions, questions of its safety in those of childbearing In 1951, aminopterin was used for the first time age are likely to become increasingly important. The for patients with a connective tissue disease, with aim of this review is to aid clinicians in the counselsix out of seven patients with rheumatoid arthritis ling and education of patients taking or about to experiencing some benefit. The authors commented, start taking low-dose MTX. We examine the effects 'The toxic effects of aminopterin place practical of MTX with respect to fertility, pregnancy and limitations on its use as a therapeutic agent'.5 lactation, based upon information obtained using MTX (amethopterin) is a methyl-derivative of amin-'Medline' search strategies from 1966 to 1997, hand opterin and was first described in 1947.3 Work search through the last ten years of the journal suggesting MTX had a wider therapeutic index than Teratology, source paper references and data from aminopterin when used in mice led to rapid the UK National Teratology Information Service ascendance over its predecessor.6 Like aminopterin, (NTIS) from 1992.
MTX is both a folate analogue and a folate antagonist. Because folates are used in the transfer of onecarbon units, they are crucial to the synthesis of purines, thymidine and amino acids. The enzyme Background dihydrofolate reductase (DHFR) is reversibly inhibited MTX is a derivative of the folic acid analogues. The by MTX. DHFR reduces folic acid to tetrahydrofolic importance of folic acid, a B group vitamin, in acid, and MTX therefore limits the availability of haematopoiesis was realized in the early 1940s, and one-carbon fragments necessary for the synthesis of by 1946 it had been synthesized and given its purines, and interferes with the conversion of deoxchemical term, pteroylglutamic acid.2 By the followyuridylate to thymidylate in the synthesis of DNA ing year, the synthesis, anti-bacterial and antiand cell reproduction.7 MTX is further metabolized metabolic actions of its 4-amino derivative, aminopto MTX polyglutamases, long-lived metabolites which terin, had been described. 3 The megaloblastic also inhibit other folate-dependent enzymes. It has appearance of marrow in some cases of leukaemia, been suggested that the efficacy of MTX may be related to these latter effects.8 similar to that seen in folic acid deficiency, led early The precise molecular mechanism by which MTX lower in women who had given birth to babies with CNS defects.17 suppresses inflammation is unknown, but it has effects on endothelial cell growth, chemotaxis, polyaAs a result of these studies, intervention trials were performed to look at the effect of folic acid mine synthesis, neovascularization and various cytokine activities, as well as suppressing the generation supplementation in pregnancy. 
Animal studies
prevention of NTD has also been suggested by a The importance of folic acid in embryonic developlarge trial of 4156 women randomized to receive ment was soon realized. Initial work using rats either a trace element tablet or vitamin mineral tablet showed that folate deficiency had a lethal effect on containing 0.8 mg folic acid. There were no NTD in embryos; the number dying being directly related to the vitamin mineral group and six in the control the duration of deficiency prior to conception.11 group.22 However, the trial design was such that the Further rat studies showed that folic acid deficiency effect of folic acid alone could not be proven. could also cause embryonic deformities, the most Although trial evidence strongly supports the role common being cleft palate and limb abnormalities.
of folic acid supplementation in the prevention As would be expected, folate deficiency after the of NTD, it has been difficult to confirm that folic thirteenth day of a 21-day gestation (i.e. after the acid deficiency produces NTD in humans. Most critical period of organogenesis) was associated with studies have shown only small or no differences a marked reduction in the number of abnormalities. 12 in RBC folate levels between women with affected Closed neural tubes but poor brain development and unaffected pregnancies and no difference in were seen in rat embryos cultured on folate-deficient dietary folate in women with affected pregnancies. serum,13 and neural tube defects have been demonAlthough the UK has one of the highest rates of NTD strated in embryos of folic-acid-deficient rats.14 The in the world, the UK diet is not particularly low in effect of folic acid deficiency on the fetus appears folate, daily intake in UK women being similar to to be species-dependent. Mice fed varying amounts that in US women (0.4 mg/day), but more than in of folic acid showed an apparent threshold for fetal Canadian women.23 It is possible that the range of resorption without the development of abnormalities.
folic acid intake and levels in the population may This pattern of abortion rather than abnormality be too small for differences to be detected in studies suggests either the presence of major fetal abnormalto date,24 or that the effect of folate deficiency ities leading to abortion, or a specific abortifacient in NTD is not direct. The influence of other factors effect.15 has been suggested, in particular homocysteine, as high levels, possibly secondary to reduced methion-
Human studies
ine synthase activity, have been noted in women carrying a fetus with NTD.25 As a result of this body It was not until the 1960s that a role for folic acid deficiency was suspected in human neural tube of evidence, folic acid supplementation is now routinely advised in the first trimester of pregnancy. defects (NTD). These defects include anencephaly, meningocele, myelomeningocele, encephalocele and spina bifida cystica. In 1965, it was suggested that Folic acid antagonists in pregnancy: animal women with lower levels of folic acid had a higher studies incidence of fetal abnormalities, particularly those of the central nervous system.16 Later studies showed Embryonic growth delay induced by folic acid antagonists was first described in chickens. 26 Later work that levels of red-cell folate, directly measured, were in this species suggested that the limb abnormalities lymphomas. The aminopterin syndrome six patients with RA, one with juvenile RA and one The first suggestions that folic acid antagonists were with allergic angiitis.37 teratogenic in humans were based on the reports of Feldkamp suggests that the threshold dose of MTX failed terminations in mothers given aminopterin in required to produce defects is 10 mg weekly, and the first trimester (Table 1 ). All reports of abnormality that the vulnerable period of gestation is between 6 include neural tube, skull or limb problems, with and 8 weeks. Using this concept, they successfully gestational ages at exposure ranging from four advised a patient to continue her pregnancy.38 The to 12 weeks. patient reported by Milunsky et al. had a 'grossly The pattern of abnormalities seen in these case irregular' menstrual cycle, but the gestational age of reports gave rise to the description 'aminopterin exposure was 8 to 10 weeks, rather than the 6 to 8 syndrome'.33 Although widely mentioned in the suggested by Feldkamp.39 literature, the only other full description of the Donnenfield used information from 63 centres 'syndrome' is given by Buckley et al.34 (Table 2) , participating in the prospective evaluation of fetal using many of the features described by Powell.35 abnormalities, and felt that the data obtained supDextrocardia, however, does not appear to be a ported the observations of Feldkamp in that the common feature in the cases reported. gestation period of 6 to 8 weeks was a critical period in methotrexate teratogenesis, and that a critical
Methotrexate in malignant conditions
weekly dosage was >10 mg.40 These assumptions remain speculative. MTX is a common constituent of multi-drug regimens in malignancies, in particular leukaemias and Buckley et al. report the only case of fetal abnor- In addition to the cases detailed above, the NTIS 7.5 mg MTX for rheumatoid arthritis sometime has been informed of three other cases of in between 4 and 7 weeks gestation. An emergency utero MTX exposure which have been lost to caesarean section for placenta praevia was performed follow-up. at 28 weeks, and the baby had a number of The Medicines Control Agency has reports of three abnormalities: respiratory distress syndrome, positive abnormal fetuses resulting from single-agent MTX sweat test for cystic fibrosis, and ileal perforation.
exposure between 1963 and 1997. The abnormalities One baby probably exposed to MTX 10 mg twice are described as hydrocephalus, nail disorder and weekly between 0 and 6 weeks gestation in a mother multiple congenital abnormalities. No details regardwith scleroderma was born normal.
ing gestational age at exposure, background disease or dose are available.
Methotrexate in late pregnancy
Donnenfield reports a healthy baby born following
Methotrexate exposure before conception exposure to 42 mg intravenous MTX at between 37 and 38 weeks gestation. No details of fetal blood After administration, methotrexate is widely distributed in body tissues, the highest concentrations being counts are given, although the baby developed pneumonia at one month of age.40 There are a in the kidneys, gallbladder, spleen, liver and skin. Its presence in the liver has been reported up to 116 further two cases of MTX given in association with 6-mercaptopurine, one at 7.5 to 8.5 months gestation days after exposure, although the amount of drug retained does not appear to be related to the dose and one at 4 to 5 months gestation. No abnormalities were seen in the fetuses, who were followed up for received.7,49 There is thus a theoretical risk of fetal exposure in babies of mothers who have taken the over 1 year.41 Rubatelli reports two cases of severe psychological abnormality in fetuses exposed in the drug up to 4 months prior to conception. summarizes the largest prospective study of pregstudy looked at 368 pregnancies in 210 women who had had single-and combined-agent chemotherapy nancy outcome in women on MTX prior to conception.40 It is also the only study where low-dose MTX for gestational trophoblastic tumours over a 20-year period. All patients were given MTX, followed in the was used within 1 year of pregnancy. A high rate of spontaneous abortion is seen (as mentioned above), majority by folinic acid. The mean duration between cessation of treatment and pregnancy was 2.7 years, but there were no abnormalities of surviving fetuses. However, the numbers (nine in total) are small. A the mean cumulative dose of MTX around 1.2 g, and the maximum dose over 6 g. Abnormalities the 11 men who had received MTX (possibly among other agents).54 There is a case report of a 34-yearincluded two anencephalic stillbirths, and one case each of spina bifida, tetralogy of Fallot, talipes old man with Reiter's syndrome who had received intermittent MTX for 5 years, and continuous MTX equinovarus, collapsed lung and umbilical hernia. One child of a mother who had received MTX for 5 months prior to conception, who fathered a normal child.55 As the duration of individual spermadeveloped desquamative fibrosing alveolitis 1 month after birth. The mother later gave birth to a healthy togenesis is approximately 74 days, it would seem sensible to add this figure to the (minimum) 4 months child, but 3 years later, a further child suffered the same problem. In the study overall, there was a needed for MTX excretion before attempting conception. slightly higher but statistically insignificant incidence of stillbirth and congenital abnormality compared to the expected background rate. 50 In an earlier report Summary of evidence for methotrexate as a of a smaller number of patients, presumably from possible teratogen the same sample, the authors describe four cases of abnormality in 130 women who had received MTX Teratology is a new science and its terminology is being refined. One definition of a teratogenic agent alone. The abnormalities were: umbilical hernia, doliocephaly plus talipes, anencephaly and fibrosing is 'one that acts during prenatal life to produce a permanent physical or functional defect in the offalveolitis. Again, the fetal wastage rate was not raised.51 These authors, from an oncology unit, spring' and the following criteria have been proposed to help establish the teratogenicity of a substance: advise delaying conception for a year after the cessation of chemotherapy. This advice differs from (i) proven exposure to agent at critical time(s) in prenatal development; (ii) consistent findings by two manufacturer's recommended 'washout period' before MTX cessation and conception, which varies or more epidemiological studies of high quality; (iii) careful delineation of the clinical cases, specific between 3 and 6 months.52 In order to allow for the persistence of MTX in tissues and to avoid potential defect or syndrome; (iv) rare environmental exposure associated with rare defect, three or more cases chromosomal damage to the dividing follicle, a minimum delay of 6 months would seem logical. probably required; (v) teratogenicity in experimental animals (important but not essential); (vi) the associThere is a theoretical risk of sperm mutation in males treated with MTX. However, a study looking ation should make biological sense; (vii) proof in an experimental system that the agent acts in an at men with rheumatoid arthritis on low-dose MTX found no significant chromosomal breakage.53 Green unaltered state. (i), (ii) and (iii) or (i), (iii) and (iv) are denoted as essential criteria.56 More recent definiet al. report two children with birthmarks (no further details given) and one with a skin tag out of 35 tions include the complex effects on growth, functional abnormalities, behavioural abnormalities and children born to 25 males who had received single and multiple chemotherapy in childhood or adolestransplacental carcinogenesis that may result from fetal exposure. cence. Two of the abnormal children were born to Placental transport of maternal substances is estabFolic acid supplementation and lished by the fifth week of embryonic life, and the methotrexate exposure first trimester of fetal life is the most vulnerable to
Folic acid supplementation at a dose of 400 mg daily teratogens. The neural tube closes at approximately (5 mg daily in those with a previous affected fetus) day 29 of gestation, and weeks 4-7 are the most is now recommended to all women in the presensitive for arm and leg development.57,58 Exposure conception period and during the first trimester.62 A to teratogens after the first trimester tends to cause recent review has suggested that women exposed abnormalities in growth and brain development. 56 It to MTX should continue supplementation (dose not is not necessary for drugs to cross the placenta in specified) throughout pregnancy. 63 In support of this, order to exert a teratogenic effect, although MTX is none of the three cases that we have found in which known to pass to the fetus, even after maternal folic acid supplementation was given with lowintrathecal administration. 59 dose MTX resulted in fetal abnormality. However, Table 3 lists all cases of MTX exposure during because the affinity of DHFR for MTX is far greater pregnancy with known outcome found by our search than its affinity for folic acid, complete reversal of strategy. There have been 71 exposed fetuses, 42 in the anti-folate effects of MTX requires the administrathe first trimester. Twelve cases of abnormality are tion of folinic acid. When given soon after MTX reported, ten of which involved physical abnormalitexposure in pregnant rabbits, leucovirin (a close ies. Of these twelve, nine involved skull abnormalitstructural analogue of folinic acid) virtually eliminates ies and six peripheral skeletal problems. All cases of teratogenic effects.64 Use of this agent at the equivadefinite physical abnormality occurred following first lent MTX dose (e.g. 7.5 mg weekly if prior exposure trimester exposure34,35,36,39,101 (three NTIS cases). was 7.5 mg MTX weekly) may be more logical for Four of the cases involved dosages of <20 mg/week at least 4 months following cessation of MTX adminor less, and in none was folic acid definitely istration in a woman wishing to continue the co-prescribed. The classical NTD that one might pregnancy. expect to see associated with a folic acid antagonist have not been seen. It may be that the effects of MTX and aminopterin are consequences of general cyto-
Methotrexate and abortion
toxicity, and that the abnormalities are in fact 'nonFolic acid antagonists are effective in the treatment specific'. Pregnancies exposed to cyclophosphamide of trophoblastic cancers in humans. As a result of have also resulted in craniofacial defects in monkeys this, MTX has been used as an abortifacient. A recent and hand abnormalities in humans.44 However, the study showed that a single high dose of MTX patterns of malformation are similar to those seen in (50 mg/m2) given before 8 weeks gestation causes fetuses exposed to aminopterin and are comparable abortion in over 95% of cases.65 It might therefore to results from some animal models of MTX exposure, be expected that MTX exposure in pregnancy would particularly in the rabbit. There is no obvious 'safe' lead to an increased abortion rate. There is some period of gestational exposure, as the timing of evidence for this. Out of eight cases of low-dose exposure in the four cases resulting in abnormal first-trimester MTX exposure, three cases of spontanfetuses runs weeks. The dose effect of MTX appears eous abortion were reported.37 In a prospective unpredictable, with extremely large amounts within study, there were three pregnancy losses (all first the first trimester being tolerated by some fetuses trimester) out of five cases of MTX exposure within and an abnormal fetus being born after exposure to 4 months prior to conception.40 Elsewhere in the 7.5 mg (NTIS case). Genetic differences in placental literature, however, an increased abortion rate is not and fetal response to toxins may partly explain this.
noticeable. Possible explanations for this are that: A case is reported of non-identical twins exposed to (a) early miscarriages are under-reported in this group aminopterin immediately before conception and to of women, many of whom are likely to suffer from cyclophosphamide throughout pregnancy. One twin menstrual irregularities secondary to their underlying was born with multiple (including limb) abnormalitcondition and treatment and (b) many of the cases ies, the other healthy.60 Recently a folate receptor of exposure will involve exposure after 8 weeks has been identified in placental tissue; MTX effects gestation. could conceivably be modified by allelic variations.61
Even allowing for the fact that the number of unaffected pregnancies complicated by MTX adminLong-term effects of methotrexate istration may be underestimated by this review, the treatment in pregnancy fetal abnormality rate appears to be significantly higher than the background rate of 2-3.5%; a rate
There is a theoretical risk of chromosomal damage, and therefore cancer and second-generation abnorwhich rises to around 5% in childhood as less obvious abnormalities are detected. mality risk, in fetuses exposed to cytotoxic agents.
Chromosome gaps and a ring chromosome were reported 26 psoriatic males who had semen analysis before treatment and 70 days after MTX 25 mg seen in the child of a mother who received intrathecal MTX among a cocktail of anti-metabolite weekly for 10 weeks. Five subjects also had testicular biopsies. There was no difference in sperm count, agents for acute lymphoblastic leukaemia.59 Breaks, gaps, fragments and extra chromosomes have been mobility or abnormal forms, and no abnormality was seen in the biopsies.74 found in leucocyte cultures from patients on MTX.66 However, larger follow-up studies have not shown
On the basis of the limited data available, fertility after low-dose MTX would seem to be only margindefinite long-term effects on children, although the number of exposed fetuses is small. Koslowski folally affected. lowed up exposed babies for a mean of 11.5 years; no abnormalities developed other than a minor Methotrexate and breast feeding speech impediment which resolved with speech MTX is excreted into breast milk in low therapy.37 Cohen67 found no increased cytogenetic concentrations; MTX concentrations in milk are less abnormality in seven children born to mothers who than 10% of those in plasma.75 It is not known had received MTX and/or actinomycin D prior to whether these small amounts are potentially harmful pregnancy. Two studies looking at total of 59 children to the developing child. In the absence of a clear exposed in a range of trimesters (including 14 evidence base, and because there is a danger of exposed to MTX) for up to 22 years showed no accumulation within fetal tissues, paediatric advice apparent adverse effects. Assessment included neurosuggests avoidance of MTX during breast feeding.76 logical and psychological testing (with comparison This advice seems logical. against a control group). Chromosomal analysis from marrow samples in the exposed children showed no abnormalities.68,69 A large study looked at 2308 offspring of survivors of child and adolescent cancer,
Conclusions
25% of whom were treated with chemotherapy. Details of the type of chemotherapy are not given, MTX demonstrates significant teratogenicity. Skull and limb abnormalities are most frequent. The effects but no increased risk of cancer was seen, although follow-up was limited to the second decade of life. 70 are unpredictable, making counselling difficult in individual cases. Depending on the condition being Six cases of high-dose MTX given after the 28th week of gestation are reported. After a follow-up treated and the age of the mother the risk of abnormality and its consequences may be seen as of 13 years, two children showed grossly disturbed psychological development, though normal physical acceptable. Women wishing to continue with a pregnancy development. In both of the affected cases the mothers had died shortly after birth from cancer.
following exposure to MTX in the first trimester can be informed that there is a 10/42 chance of abnormalFour other children whose mothers had been treated with similar MTX regimens were unaffected. 42 ity in the fetus on the basis of data from cases of MTX exposure. Four out of 13 cases of low-dose Although there is a theoretical risk of chromosomal aberration causing long-term effects in babies (<20 mg/week) exposure have resulted in abnormal fetuses. This incidence of abnormality is at least exposed to MTX in utero, the studies to date do not confirm the risk. However, follow-up time is limited.
twice that seen following anti-convulsant exposure, where women are given an overall risk of malformaMost of the small amount of data comes from cases in which oncological doses of MTX were used; the tion of around 10%. In cases of MTX exposure, the drug should be risk with low-dose MTX (which has not been shown to be associated with an increased risk of neoplasia71) stopped and women wishing to continue the pregnancy should, following counselling, be offered treatmay be less. ment with folinic acid for at least 5 months in order to minimize MTX effects on the fetus.
Methotrexate and fertility
Women should be warned that there may be a small increased risk of spontaneous abortion early The risk of infertility appears low even after highdose MTX. One review reports a 97% conception in pregnancy, and advised against taking MTX if they are considering conception. Those who choose to rate in women 1 year or more after cessation of MTX treatment.50 Oligospermia has been reported in assostop MTX and proceed to pregnancy should be advised against conception within 6 months of ciation with MTX treatment,72 but a detailed study looking at a small number of men and women during taking MTX. In the event of conception within this time, full counselling and close fetal monitoring and after high-dose MTX treatment (up to 400 g) for osteosarcoma showed no long-term effect on should be offered. MTX treatment is unlikely to have a major effect ovarian or testicular function.73 A further study embryos in folic-acid-deficient serum. Teratology 1989; on short-or long-term fertility in men and women, 
